HALIFAX, Nova Scotia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI, OTC:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, is pleased to announce that it has closed the second tranche of its previously announced non-brokered private placement for aggregate gross proceeds of C$100,000 (the "Private Placement").
The Private Placement consisted of the issuance and sale of 4,000,000 units of the Company (the "Units") at a price of C$0.025 per Unit. Each Unit issued pursuant to the Private Placement consists of one Class A common share of the Company (a "Common Share") and one-half of one Common Share purchase warrant of the Company (each whole warrant, a "Warrant"). Subject to receipt of shareholder approval, each Warrant will entitle the holder to acquire one Common Share at a price of C$0.05 per Common Share for 36 months from the closing date of the Private Placement (the "Closing Date").
Pursuant to the requirements of the Toronto Stock Exchange (the "TSX"), the Warrants will not be exercisable until such time as the Company obtains requisite shareholder approval (which for certainty will exclude the votes of holders of Warrants), such approval to be sought no later than the next Annual General Meeting of the Company's shareholders. If the Warrants do not receive shareholder approval, the Warrants will not be exercisable.
The Company intends to use the net proceeds from the Private Placement primarily for working capital purposes and to fund the development of certain product candidates of the Company.
In connection with the second tranche closing, the Company has also paid certain finders an aggregate of C$8,000 and ...
